Equities Analysts Issue Forecasts for ENTA FY2029 Earnings

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Analysts at HC Wainwright issued their FY2029 EPS estimates for shares of Enanta Pharmaceuticals in a research note issued on Tuesday, December 24th. HC Wainwright analyst E. Arce expects that the biotechnology company will earn ($6.62) per share for the year. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($4.73) per share.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.20). The firm had revenue of $14.60 million for the quarter, compared to the consensus estimate of $17.99 million. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. The company’s revenue for the quarter was down 22.8% on a year-over-year basis. During the same period in the prior year, the business earned ($1.33) earnings per share.

Other analysts have also issued research reports about the stock. JMP Securities reissued a “market outperform” rating and issued a $21.00 price target (down previously from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. Robert W. Baird dropped their price objective on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 26th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $17.25.

Enanta Pharmaceuticals Stock Performance

Shares of NASDAQ:ENTA opened at $6.00 on Wednesday. The firm has a market cap of $127.16 million, a PE ratio of -1.09 and a beta of 0.49. Enanta Pharmaceuticals has a twelve month low of $5.70 and a twelve month high of $17.80. The business has a fifty day moving average of $9.40 and a 200-day moving average of $11.57.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ENTA. Allspring Global Investments Holdings LLC acquired a new position in shares of Enanta Pharmaceuticals in the second quarter valued at $35,000. US Bancorp DE lifted its position in Enanta Pharmaceuticals by 4,933.7% during the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 4,243 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Enanta Pharmaceuticals during the 3rd quarter worth approximately $122,000. Quest Partners LLC boosted its holdings in shares of Enanta Pharmaceuticals by 511.2% in the 2nd quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 9,692 shares in the last quarter. Finally, Valence8 US LP acquired a new stake in Enanta Pharmaceuticals in the third quarter valued at about $207,000. Institutional investors own 94.99% of the company’s stock.

Insider Transactions at Enanta Pharmaceuticals

In other news, CEO Jay R. Luly sold 5,142 shares of the company’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $8.06, for a total transaction of $41,444.52. Following the sale, the chief executive officer now owns 801,638 shares in the company, valued at $6,461,202.28. This represents a 0.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 13.64% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.